Takeda Targets Rival Over Generic Diabetes Drug

Law360, New York (November 21, 2011, 5:03 PM EST) -- Takeda Pharmaceutical Co. Ltd. launched its latest attack Wednesday in New York federal court seeking to prevent generic-drug maker Hetero Drugs Ltd. and several subsidiaries from producing their own version of the blockbuster diabetes drug Actos.

Japan-based Takeda and its Takeda Pharmaceuticals North America unit allege that Hetero's submission of an abbreviated new drug application seeking U.S. Food and Drug Administration approval for tablets containing pioglitazone, an active ingredient in Actos, infringes seven Takeda patents.

“Unless Hetero is enjoined from infringing and inducing the infringement of...
To view the full article, register now.